Mayne Pharma reports quarterly EBITDA drop to $5.3M
Key points
- Mayne Pharma Group reported a 52% decrease in first-quarter underlying EBITDA to $5.3 million.
- First-quarter revenue fell 2% to $95.7 million, while the share price traded lower at $2.45.
- Strategic growth in the Women's Health segment was offset by expected competitive erosion in dermatology sales.
Mayne Pharma (ASX:MYX) reported a 52% drop in first-quarter underlying EBITDA to $5.3 million.
The quarterly underlying EBITDA fell from $11. Million in the prior corresponding period, while revenue slipped to $95.7 million.
"The first quarter of FY27 delivered continued strong prescription growth across our Women's Health portfolio, driven by our growth strategy, and saw further momentum in DistributeRx," said Mayne Pharma CEO Aaron Gray.
During the period, the business settled legacy generic drug pricing litigation for a one-time payment of US$0.7 million.
The business also entered into an exclusive five-year licensing deal with Italfarmaco for BLISSEL in Australia.
Following the announcement, the Mayne Pharma share price was down at $2.45.
Mayne Pharma operates as a speciality pharmaceutical business focused on commercialising branded and generic products.
The business continues to expand its digital pharmacy platform, DistributeRx, alongside its core portfolio offerings.
Frequently asked questions
More from Australia
Pinnacle Minerals secures option over US tungsten projects
Invex to acquire Rekover Therapeutics in deal
Marmota doubles Greenewood high-grade gold strike length
CZR Resources seeks ASIC consent to cancel takeover
AML3D secures $2.2M Northrop Grumman deal
Beforepay revenue reaches $16.5M in record quarter
